The US Food and Drug Administration (FDA) is requiring manufacturers of GLP-1 medicines to update their safety labels to warn of a potential increased risk of a rare but serious eye condition that can cause permanent vision loss.
The US Food and Drug Administration (FDA) is requiring manufacturers of GLP-1 medicines to update their safety labels to warn of a potential increased risk of a rare but serious eye condition that can cause permanent vision loss.
Comments
Top comments